Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 4/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13218978 | 1.00 | ALDH1A1 (0.33) | ALDH1A1LMNAMIFHDAC6CYP3A4 | |
| SCHEMBL13238853 | 0.80 | PRSS1 (0.33) | CYP2C9CYP2C19 | |
| SCHEMBL13218977 | 0.80 | PRSS1 (0.33) | CYP2C9CYP2C19 | |
| SCHEMBL17581885 | 0.79 | MIF (0.41) | MIFHDAC6CYP3A4MAPTCYP2C9 | |
| SCHEMBL28359043 | 0.75 | CYP3A4 (0.37) | MIFHDAC6CYP3A4MAPTCYP2C9 | |
| SCHEMBL8783870 | 0.75 | CYP3A4 (0.37) | ALDH1A1LMNACYP3A4MAPTCYP2C19 | |
| SCHEMBL8783865 | 0.75 | CYP3A4 (0.37) | ALDH1A1LMNACYP3A4MAPTCYP2C19 | |
| SCHEMBL8704531 | 0.72 | PRSS1 (0.33) | — | |
| SCHEMBL8704527 | 0.72 | PRSS1 (0.33) | — | |
| SCHEMBL8704532 | 0.72 | PRSS1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100217019-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF NEW ACTIN-TARGETING SMALL-MOLECULE AGENTS | THE UNIVERSITY OF CHICAGO | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217019-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF NEW ACTIN-TARGETING SMALL-MOLECULE AGENTS | ACTR2, ACTR3, ACTB | ALDH1A1 4394/4885LMNA 2237/4885MIF 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.